We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+4.89%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$10.9M
AUM Growth
-$6.11M
(-36%)
Cap. Flow
-$3.99M
Cap. Flow
% of AUM
-36.67%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
16
New
2
Increased
4
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.5M |
| 2 |
Incyte
INCY
|
+$827K |
| 3 |
DexCom
DXCM
|
+$770K |
| 4 |
ATHN
Athenahealth, Inc.
ATHN
|
+$757K |
| 5 |
PETX
Aratana Therapeutics, Inc.
PETX
|
+$714K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$2.32M |
| 2 |
Gilead Sciences
GILD
|
+$1.69M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$838K |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$816K |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$799K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.18% |
| 2 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.64M | 15.09% |
+8,599
| New | +$1.5M |
|
|
2
Incyte
INCY
$24.9B
| $1.6M | 14.72% |
14,756
+7,412
| +101% | +$827K |
|
3
Regeneron Pharmaceuticals
REGN
$77.4B
| $1.58M | 14.56% |
2,916
+1,160
| +66% | +$628K |
|
|
4
DexCom
DXCM
$28.8B
| $1.56M | 14.35% |
76,184
+37,008
| +94% | +$770K |
|
|
PETX
5
DELISTED
Aratana Therapeutics, Inc.
PETX
| $1.22M | 11.21% |
218,515
+107,978
| +98% | +$714K |
|
6
Acadia Pharmaceuticals
ACAD
$4.55B
| $1.06M | 9.77% |
29,801
-19,024
| -39% | -$670K |
|
|
ATHN
7
DELISTED
Athenahealth, Inc.
ATHN
| $789K | 7.26% |
+4,900
| New | +$757K |
|
8
Eli Lilly
LLY
$1.03T
| $750K | 6.9% |
8,898
-7,946
| -47% | -$659K |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
| $364K | 3.35% |
14,962
-16,000
| -52% | -$373K |
|
|
10
Edwards Lifesciences
EW
$50B
| $303K | 2.79% |
114,966
-89,448
| -44% | -$2.32M |
|
|
11
Gilead Sciences
GILD
$163B
| – | – |
-17,162
| Closed | -$1.69M |
|
12
Neurocrine Biosciences
NBIX
$18.7B
| – | – |
-17,386
| Closed | -$692K |
|
13
United Therapeutics
UTHR
$26.2B
| – | – |
-2,500
| Closed | -$328K |
|
|
MNK
14
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – |
-12,769
| Closed | -$816K |
|
|
MDCO
15
DELISTED
Medicines Co
MDCO
| – | – |
-22,077
| Closed | -$838K |
|
|
MDVN
16
DELISTED
MEDIVATION, INC.
MDVN
| – | – |
-18,794
| Closed | -$799K |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q4 2015 Portfolio in Review
As of Q4 2015, March Altus Capital Management held 16 positions worth $10.9M, down 36% from $17M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
March Altus Capital Management withdrew a net $3.99M in Q4 2015, closing 6 positions and reducing 4 holdings. Its most notable exit was Gilead Sciences, an estimated $1.69M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier, followed by Industrials.
Against the trend, March Altus Capital Management opened a new position in Alexion Pharmaceuticals worth $1.64M.
- March Altus Capital Management's largest Q4 2015 buy was Alexion Pharmaceuticals: 8,599 shares worth $1.64M.
- March Altus Capital Management added most to Incyte in Q4 2015, an estimated $827K increase.
- March Altus Capital Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $2.32M.
- March Altus Capital Management fully exited Gilead Sciences in Q4 2015, selling an estimated $1.69M.
- March Altus Capital Management's ten largest holdings make up 100% of its $10.9M portfolio in Q4 2015.
- March Altus Capital Management opened 2 new positions and closed 6 in Q4 2015.
- March Altus Capital Management's portfolio value fell 36% quarter-over-quarter to $10.9M.
Based on March Altus Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.